The most popular stories and special reports in FierceBiotech Research, FiercePharmaManufacturing, and the rest of our Life Sciences publications

We hope you've found this year's roundup of the most popular content on the web interesting. Below, you'll find the top-visited stories and special reports from each of our weekly and semi-weekly publications this year. The content is listed by popularity in descending order.

We'll be back on Monday with our regular coverage. Enjoy the leftovers.

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.

The RNAi therapy drove a 72% reduction in urinary oxalate from baseline, boosting Alnylam’s hopes of using the drug in a broad patient population.